Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy (OU-SCC-NCAN)
Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy: A First in Human Randomized Pilot Study. Neuromodulation in Cancer Study (OU-SCC-NCAN)
Sponsor: University of Oklahoma
This EARLY_PHASE1 trial investigates Breast Cancer and Lymphoma and is currently actively recruiting participants. University of Oklahoma leads this study, which shows 11 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Feb 2026 — Present [monthly]
Recruiting EARLY_PHASE1
Phase: NA → EARLY_PHASE1
-
Nov 2025 — Feb 2026 [monthly]
Recruiting NA
-
Sep 2025 — Nov 2025 [monthly]
Recruiting NA
-
Jun 2025 — Sep 2025 [monthly]
Recruiting NA
-
Mar 2025 — Jun 2025 [monthly]
Recruiting NA
▶ Show 6 earlier versions
-
Sep 2024 — Mar 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Jan 2024 — Jul 2024 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Dec 2023 — Jan 2024 [monthly]
Not Yet Recruiting NA
-
Nov 2023 — Dec 2023 [monthly]
Not Yet Recruiting NA
-
Jul 2023 — Nov 2023 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Oklahoma
For direct contact, visit the study record on ClinicalTrials.gov .